Company Active LTD

Company profile

Sierra Medical Ltd

Sierra Medical Intelligent health

Sierra Medical Ltd is a UK company with status active founded in 2021 based in East Midlands.

CRN
13115958
Founded
2021
Age
5

Overview

Legal name
SIERRA MEDICAL LTD
Region
East Midlands
Registered address
KETTON SUITE, THE KING CENTRE MAIN ROAD
BARLEYTHORPE
OAKHAM
RUTLAND
ENGLAND
LE15 7WD
Insolvency history
No

Latest accounts

Financial period: 1 Feb 2024 to 31 Jan 2025

FILLETEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
4

Company events

Reference milestones and recent Companies House filing stream events.

8 events
19 Jan
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Oct
2026

Accounts due

Accounts Due

Next accounts due date

05 Jan
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Jan
2025

Accounts filed

Accounts

Last accounts made up date

21 Nov
2024

Capital Allotment Shares

Capital

SH01 | Transaction MzQ0NDQ5NTUxNmFkaXF6a2N4

Published 21 Nov 2024 10:03

18 Nov
2024

Capital Allotment Shares

Capital

SH01 | Transaction MzQ0MzY5OTcyOWFkaXF6a2N4

Published 18 Nov 2024 11:34

02 Oct
2024

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzQzODE0ODUwN2FkaXF6a2N4

Published 02 Oct 2024 02:03

06 Jan
2021

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2018
Funded years
2018, 2022, 2023
Age at first award
-2 years

Projects

2023 EU-Funded Lead participant

New AI-based method for early detection of lung cancer

1 Apr 2023 to 31 Mar 2025

Awarded
£2,155,015
Total cost £2,155,015

no public description

2022 Collaborative R&D Lead participant

SM-S1: An early lung cancer detection test

1 Dec 2022 to 30 Nov 2023

Awarded
£336,244
Total cost £747,209

Cancer is the leading cause of illness worldwide. Each year, about 1.8 M deaths are caused by lung cancer (LC). Early diagnosis is crucial to improve survival rates. However Stage I-III LC is asymptomatic or non-descript (e.g. a cough) and often ascribed to "getting older" or, more recently, COVID. Consequently about 75% of patients are diagnosed at the l...

2018 Collaborative R&D Lead participant

Solas-Lung

1 Nov 2018 to 30 Jun 2021

Awarded
£465,560
Total cost £665,083

_Solas-Lung_ reinforces a partnership between BeamLine and University College London (UCL) with the primary project aim to complete the 400 patient first in clinic trial required for developing our technology towards regulatory approval: advancing _Solas-Lung_ to TRL6/7\. UCL have supported IR detection of cancerous cells with \>10 years of ground-breakin...

Product types

Collaborative R&D EU-Funded